Equillium to Participate in Stifel’s 2026 Virtual Immunology and Inflammation Forum
Equillium Inc EQ
$1.67
▼ -2.91%
($-0.05)
Open
$1.70
Prev Close
$1.72
Day Range
$1.66 – $1.71
52W Range
$0.76 – $3.54
Market Cap
$105.89M
Beta
2.08
EPS (TTM)
$-0.32
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2018-10-12 |
| Shares Out. | 63,230,000 |
| Website | equilliumbio.com/home/default.aspx ↗ |
| Phone | 18009279800 |
| Employees | 14 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$4.7M |
| Free Cash Flow | -$20.1M |
| Total Assets | $58.7M |
| Total Liabilities | $2.7M |
| Equity | $56.0M |
About Equillium Inc
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
Equillium Inc is a publicly traded company under the ticker symbol EQ on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
18 analysts (2026-09-01)